Lupin share news, announcements and annual reports
NSE: LUPINBSE: 500257Pharmaceuticals & BiotechnologyMid Cap
Lupin Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1993 on BSE, Sep 2001 on NSE
Last close ₹1,996.50down ₹14.50 (0.72%)BSE ₹1,996.55
Share price at the NSE close on 2 Nov 2026. Previous close ₹2,011.00.
2 Nov: open ₹2,019.80, high ₹2,033.80, low ₹1,996.50
52-week range of traded prices to 2 Nov 2026
₹1,892.90Low, 23 Oct 2026₹2,529.50High, 16 Jul 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹91,298 Cr105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 16.51
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹558 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 15.00
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹558 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 30.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 28.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.26
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,64,79862.6% delivered
Lupin share news and announcements
2,114 announcements, routine notices left out, newest first. Page 38 of 43.
Nov 2010
1 Nov · Management
Board of Directors of the Company at their meeting held on November 01, 2010, the Board has:-(1) Re-appointed Dr. Desh Bandhu Gupta as Executive Chairman and Mrs. M. D. Gupta as Executive Director of the Company, for a period of five years w.e.f. January 01, 2011. The same shall be subject to approval of the shareholders.1 Nov · Results
Consolidated Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 140505 lacs for quarter ending on 30-SEP-2010 against Rs. 111469 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 21502 lacs for the quarter ending on 30-SEP-2010 against Rs. 16030 lacs for the quarter ending on 30-SEP-2009.1 Nov · Results
Standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 104869 lacs for quarter ending on 30-SEP-2010 against Rs. 80687 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 16239 lacs for the quarter ending on 30-SEP-2010 against Rs. 9837 lacs for the quarter ending on 30-SEP-2009.
Oct 2010
20 Oct · Board meeting
Inter alia, to consider the unaudited financial results for the quarter ended September 30, 2010.19 Oct · Business
Allotment Committee of Directors at its meeting held on October 19, 2010 has allotted 95650 fully paid up equity shares of Rs. 2/- each. These shares have been allotted upon exercising of options granted to the employees under stock option plans of the Company. In view of the above, the issued and paid up capital of the Company has been increased to Rs. 89,15,42,140 consisting 44,57,71,070 equity shares of Rs. 2/- each.
Sep 2010
29 Sep · Updates
Lupin Holdings B. V. (LHBV) Netherlands, a wholly-owned subsidiary of the Company, was holding 49.91% equity stake in Generic Health Pty. Ltd. (Generic Health), Australia, an Associate of the Company. LHBV has now acquired a majority stake in the Generic Health on account of subscription to the right issue of shares. Accordingly, Generic Health has become a subsidiary of the Company20 Sep · Business
Allotment Committee of Directors at its meeting held on September 20, 2010 has allotted 102800 fully paid up equity shares of Rs. 2/- each. These shares have been allotted upon exercising of options granted to the employees under stock option plans of the Company. In view of the above, the issued and paid up capital of the Company has been increased to Rs. 89,13,50,840 consisting 44,56,75,420 equity shares of Rs. 2/- each.
Aug 2010
26 Aug · Disclosure
Company has granted 34500 options to its employees under "Lupin Employees Stock Option Plan 2003", 37000 options to its employees under "Lupin Employees Stock Option Plan 2005" and 20000 options to the employee of its subsidiary company under "Lupin Subsidiary Companies Employees Stock Option Plan 2005" at the exercise price of Rs.1854.85 on August 23, 2010. Further one equity share of Rs.10/- each is covered by each option. The option issued are exercisable at the 'market price' as defined in SEBI guidelines, in a phased manner after a minimum vesting period of 12 months but before the exercise period of 10 years from the date of grant.13 Aug · Business
Allotment Committee of Directors at its meeting held on August 13, 2010 has allotted 20714 fully paid up equity shares of Rs. 10/- each. These shares have been allotted upon exercising of options granted to the employees under stock option plans of the Company. In view of the above, the issued and paid up capital of the Company has been increased to Rs. 891,145,240 consisting 89,114,524 equity shares of Rs. 10/- each.
Jul 2010
28 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 131209 lacs for quarter ending on 30-JUN-2010 against Rs. 108559 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 19630 lacs for the quarter ending on 30-JUN-2010 against Rs. 14011 lacs for the quarter ending on 30-JUN-2009.28 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 99707 lacs for quarter ending on 30-JUN-2010 against Rs. 91090 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 15742 lacs for the quarter ending on 30-JUN-2010 against Rs. 17958 lacs for the quarter ending on 30-JUN-2009.15 Jul · Business
Allotment Committee of Directors at its meeting held on July 15, 2010 has allotted 26764 fully paid up equity shares of Rs. 10/- each. These shares have been allotted upon exercising of options granted to the employees under stock option plans of the Company. In view of the above, the issued and paid up capital of the Company has been increased to Rs. 890,938,100 consisting 89,093,810 equity shares of Rs. 10/- each.14 Jul · Board meeting
Inter alia, to consider the unaudited financial results for the quarter ended June 30, 2010.8 Jul · Meeting
Annual General Meeting of the Company will be held on July 28, 2010. Further the Board of Directors at their meeting held on May 5, 2010 have decided to close the Register of Members and Share Transfer Register from July 21, 2010 to July 28, 2010 (both days inclusive) for the purpose of Annual General Meeting and Dividend.7 Jul · Business
The Allotment committee Of Directors at its meeting held on July 07,2010 has allotted 67227 fully paid up equity shares of Rs. 10/- Each. These shares have been allotted upon exercising of options granted to the employees under the stock option plans of the Company. In view of the above, the issued and paid up capital of the Company has been increased to Rs.890,670,460 consisting 89,067,046 equity shares of Rs. 10/- each
Jun 2010
8 Jun · Business
Allotment Committee of Directors at its meeting held on June 08, 2010 has allotted 15414 fully paid up equity shares of Rs. 10/- each. These shares have been allotted upon exercising of options granted to the employees under Stock Option plans of the Company. In view of the above, the issued and paid up capital of the Company has been increased to Rs. 889,998,190 consisting 88,999,819 equity shares of Rs. 10/- each.
May 2010
28 May · Business
Hon'ble Bombay High Court sanctioned the scheme of amalgamation of Lupin Pharmacare Limited and Lupin Herbal Limited (Transferor Companies), wholly-owned subsidiaries of Lupin Limited, with Lupin Limited (Transferee Company) w.e.f. April 1, 2009 ("Appointed Date"). The Hon'ble High Court of Gujarat at Ahmedabad also sanctioned the scheme of amalgamation of Novodigm Limited (Transferor Company), another wholly-owned subsidiary of Lupin Limited, with Lupin Limited (Transferee Company) w.e.f. April 1,2009 ("Appointed Date). Further, the Court Orders have been filed with the Registrar of Companies.14 May · Business
Allotment Committee of Directors at its meeting held on May 14, 2010 has allotted 13855 fully paid up equity shares of Rs. 10 each. These shares have been allotted upon exercising of options granted to the employees under Stock Option plans of the Company. In view of the above, the issued and paid up capital of the company has been increased to Rs. 889,844,050 consisting 88,984,405 equity shares of Rs. 10 each.5 May · Management
At the meeting of the Board of Directors held on May 05, 2010, has noted the resignation of Mr. Sunil Nair from the directorship of the Company w.e.f. May 05, 2010.5 May · Share Split
At the meeting of the Board of Directors held on May 5, 2010, the Board has approved the sub-division of equity shares of the face value of Rs. 10/- each in the Company into shares with the face value of Rs.2/- each. The sub-division would be subject to the approval of the shareholders at the ensuing annual general meeting and such other approvals as may be necessary.5 May · Results
Standalone Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 364009 lacs for year ending on 31-MAR-2010 against Rs. 289856 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 64893 lacs for the year ending on 31-MAR-2010 against Rs. 41697 lacs for the year ending on 31-MAR-2009.5 May · Results
Standalone Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 91782 lacs for quarter ending on 31-MAR-2010 against Rs. 70460 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 14828 lacs for the quarter ending on 31-MAR-2010 against Rs. 8837 lacs for the quarter ending on 31-MAR-2009.5 May · Results
Consolidated Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 474052 lacs for year ending on 31-MAR-2010 against Rs. 377588 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 68163 lacs for the year ending on 31-MAR-2010 against Rs. 50154 lacs for the year ending on 31-MAR-2009.5 May · Results
Consolidated Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 128481 lacs for quarter ending on 31-MAR-2010 against Rs. 104335 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 22062 lacs for the quarter ending on 31-MAR-2010 against Rs. 15738 lacs for the quarter ending on 31-MAR-2009.5 May · Dividend
Board of Directors of the Company at its meeting held on May 05, 2010 has recommended dividend @135% i.e. Rs. 13.50 per equity share of the face value of Rs. 10/- each for the year ended March 31, 2010.
Apr 2010
29 Apr · Allotment of Equity Shares
The Allotment Committee of Directors at its meeting held on April 29, 2010 has allotted 11151 fully paid up equity shares of Rs.10/- each. These shares have been allotted upon exercising of options granted to the employees under Stock option plans of the Company. In view of the above, the issued and paid up capital of the Company has been increased to Rs. 889,705,500 consisting 88,970,550 equity shares of Rs. 10/- each20 Apr · Business
Press release dated April 20, 2010, titled " Lupin receives FDA approval for Imipramine Pamoate Capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Apr · Allotment of Equity Shares
Allotment Committee of Directors at its meeting held on April 14, 2010 has allotted 15566 fully paid up equity shares of Rs.10/- each. These shares have been allotted upon exercising of options granted to the employees under Stock option plans of the Company. In view of the above, the issued and paid up capital of the Company has been increased to Rs. 889,593,990 consisting 88,959,399 equity shares of Rs. 10/- each.13 Apr · Board meeting
Inter alia, to consider the audited accounts for the year ended March 31, 2010 and recommend dividend, if any.7 Apr · Results
The last accounting year of the Company ended on March 31, 2010 and we intend to finalise and publish the audited results for the said year within the time stipulated by Clause 41 of the Listing Agreement. In view of the above, publication of the unaudited results for the last quarter i.e. January 01, 2010 to March 31, 2010 would not be necessary.
Mar 2010
25 Mar · Business
Press release dated March 25, 2010, titled " Lupin launches Hyalgan in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Mar · Allotment of Equity Shares
Allotment Committee of Directors at its meeting held on March 22, 2010 has allotted 13125 fully paid up equity shares of Rs.10/- each. These shares have been allotted upon exercising of options granted to the employees under Stock option plans of the Company. In view of the above, the issued and paid up capital of the Company has been increased to Rs. 889,438,330 consisting 88,943,833 equity shares of Rs. 10/- each.22 Mar · Business
Press release dated March 20, 2010, titled "Lupin receives FDA tentative approval for Eszopiclone tablets". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2010
17 Feb · Allotment of Equity Shares
Allotment Committee of Directors at its meeting held on February 17, 2010 has allotted 9364 fully paid up equity shares of Rs.10/- each. These shares have been allotted upon exercising of options granted to the employees under Stock option plans of the Company. In view of the above, the issued and paid up capital of the Company has been increased to Rs. 889,307,080 consisting 88,930,708 equity shares of Rs. 10/- each.8 Feb · Business
Press release dated February 08, 2010, titled "Lupin receives US FDA approval for Amlodipine / Benazepril capsules". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
29 Jan · Business
Vide its letter dated January 29, 2010 regarding a press release dated January 28, 2010 titled "Lupin Strengthens its Board; Appoints Three Independent Directors". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Jan · Grant of Options
Company has granted 71,000 options to its employees under "Lupin Employees Stock Option Plan 2003" at the exercise price of Rs.1404.00 on January 29, 2010. Further, the Company informed that one equity share of Rs.10/- each is covered by each option. The options issued are exercisable at the 'market price' as defined in SEBI guidelines, in a phased manner after a minimum vesting period of 12 months but before the exercise period of 10 years from the date of grant.29 Jan · Management
At the meeting of the Board of Directors held on January 29, 2010 , the Board has : (1) Approved Dr. Vijay Kelkar, Mr. K. V. Kamath and Mr. Richard Zahn as Additional Directors; (2) The resignation of Mr. Marc Desaedeleer from the Directorship of the Company.